The first comment after the article ends the discussion: "This article is misleading from the beginning. India did not refuse to issue a patent for Gleevec, it

The first comment after the article ends the discussion: "This article is misleading from the beginning. India did not refuse to issue a patent for Gleevec, it refused to extend the patent Gleevec already had, based on merely superficial changes to the formula, a practice known as "evergreening", which pharmaceutical companies use to extend the monopoly on their medications as long as possible." That is completely accurate, and more informative that the article in fewer words.